Pirfenidone alleviates vascular intima injury caused by hyperhomocysteinemia

Rev Port Cardiol. 2022 Oct;41(10):813-819. doi: 10.1016/j.repc.2021.12.011. Epub 2022 Jul 16.
[Article in English, Portuguese]

Abstract

Objectives: Hyperhomocysteinemia (HHcy) can induce vascular inflammatory and oxidative damage and accelerate intimal hyperplasia. This study investigated the protective effect of pirfenidone (PFD) on the recovery process of injured endothelial arteries during HHcy.

Materials and methods: Thirty rabbits were randomly separated into three groups: A control group (n=10, standard rabbit chow), a model group (n=10, control diet plus 30 g methionine/kg food), and a PFD group (n=10, model diet plus oral administration of 90 mg/day of PFD). After 14 weeks of arterial injury, histopathological changes were determined. Plasma homocysteine (Hcy) concentrations, lipid profiles and oxidant and antioxidant status were evaluated. Macrophage infiltration was assessed using immunohistochemical staining.

Results: PFD supplementation decreased macrophage infiltration of iliac artery significantly without changes in blood lipids and Hcy concentrations. Compared with the model group, PFD restored superoxide dismutase and glutathione peroxidase activities and reduced malondialdehyde and reactive oxygen species levels. A high-methionine diet significantly increased neointimal area and the ratio between neointimal and media area. Systemic administration of PFD inhibited neointimal formation.

Conclusions: PFD can partly alleviate intimal hyperplasia by inhibiting inflammatory and oxidative stress response induced by HHcy during endothelial injury. It may be a potential therapeutic agent for the prevention and treatment of endothelial injury-associated diseases such as atherosclerosis.

Keywords: Aterosclerose; Atherosclerosis; Hiperhomocisteinemia; Hiperplasia da neoíntima; Hyperhomocysteinemia; Inflammatory response; Lesão vascular; Neointimal hyperplasia; Oxidative stress; Resposta inflamatória; Stress oxidativo; Vascular damage.

Publication types

  • Randomized Controlled Trial, Veterinary

MeSH terms

  • Animals
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use
  • Glutathione Peroxidase / pharmacology
  • Glutathione Peroxidase / therapeutic use
  • Homocysteine / pharmacology
  • Homocysteine / therapeutic use
  • Hyperhomocysteinemia* / complications
  • Hyperhomocysteinemia* / drug therapy
  • Hyperhomocysteinemia* / pathology
  • Hyperplasia / pathology
  • Lipids
  • Malondialdehyde / pharmacology
  • Methionine / pharmacology
  • Methionine / therapeutic use
  • Oxidants / pharmacology
  • Oxidants / therapeutic use
  • Pyridones
  • Rabbits
  • Reactive Oxygen Species / pharmacology
  • Reactive Oxygen Species / therapeutic use
  • Superoxide Dismutase / pharmacology
  • Superoxide Dismutase / therapeutic use
  • Tunica Intima / pathology

Substances

  • Antioxidants
  • Lipids
  • Oxidants
  • Pyridones
  • Reactive Oxygen Species
  • Homocysteine
  • Malondialdehyde
  • Methionine
  • pirfenidone
  • Glutathione Peroxidase
  • Superoxide Dismutase